Welcome to our dedicated page for Dr Reddys Labs SEC filings (Ticker: RDY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Dr. Reddy's Laboratories Limited filings document its U.S. reporting as a foreign private issuer with American depositary receipts listed on the New York Stock Exchange. Recent Form 6-K reports furnish exchange intimations and exhibits submitted to Indian exchanges and the NYSE, including board-meeting notices and other current-report disclosures.
The filing record centers on Rule 13a-16 and 15d-16 submissions, Form 20-F reporting status, governance communications, and public-company notices tied to Dr. Reddy's pharmaceutical operations and securities across India and the United States.
Dr. Reddy’s Laboratories Limited has furnished a Form 6-K as a foreign private issuer to provide investors with access to its latest communications. The filing transmits an exhibit containing the transcript of the earnings call for the quarter and financial year ended March 31, 2026.
The earnings call was conducted on May 12, 2026, and the full transcript has been made available on the company’s website via a specified weblink. The company notes this submission is made pursuant to Regulation 30 of India’s Listing Obligations and Disclosure Requirements, helping keep investors informed through publicly accessible call details.
Dr. Reddy’s Laboratories filed a Form 6-K to share its schedule of analyst and institutional investor meetings. The company’s management will attend a series of in-person group meetings at investor conferences organized by Elara Capital, Bank of America, Nomura and Investec.
Sessions are planned across multiple financial centers between May 20, 2026 and June 3, 2026, including Hong Kong, Singapore, Toronto, Boston, New York and Princeton, New Jersey. The company notes that this schedule may change if required by investors or the company.
Dr. Reddy’s Laboratories Ltd. has launched its generic Semaglutide Injection in Canada after receiving a Notice of Compliance from Health Canada on April 28, 2026. Canada is the first G7 country to grant market authorization for this product.
The once-weekly injection is indicated for adults with type 2 diabetes mellitus, to improve blood sugar control alongside diet and exercise. It is supplied as a sterile solution in pre-filled pens at 2 mg/pen and 4 mg/pen strengths, each at 1.34 mg/ml, delivering 0.25 mg, 0.5 mg, or 1 mg doses per injection.
The company highlights its established presence and market access in Canada and describes GLP-1 therapies, including semaglutide, as a key focus area. This Canadian launch follows a recent semaglutide introduction in India under the Obeda® brand and supports Dr. Reddy’s broader strategy to expand access to advanced, affordable diabetes treatments across multiple markets.
Dr. Reddy’s Laboratories reported softer FY26 results, with consolidated revenues of ₹335,933 million, up 3.2% year on year, but profit attributable to equity holders down to ₹42,850 million, a 24% decline. Full‑year gross margin fell to 52.8% from 58.5% and EBITDA margin to 22.8% from 28.3%.
Q4 FY26 was particularly weak: revenues were ₹75,162 million, down 11.6% year on year and 13.9% sequentially, with gross margin dropping to 44.8%. The company booked a ₹4,530 million Shelf Stock Adjustment on US lenalidomide, impairments of CAR‑T and Eftilagimod Alfa assets totaling about ₹2,277 million, and VAT‑related provisions of ₹1,141 million, alongside earlier VAT and New Labour Codes charges.
Despite these one‑offs, the core portfolio showed mixed trends. FY26 Global Generics revenues grew 3% to ₹299,033 million, driven by Emerging Markets (₹67,608 million, up 23%), India (₹62,186 million, up 16%) and Europe (₹55,501 million, up 55%), while North America declined 22% to ₹113,737 million on lower lenalidomide sales. The balance sheet remained strong, with equity of ₹380,457 million, a net cash surplus of ₹32,714 million and FY26 free cash flow of ₹16,888 million. The Board recommended a final dividend of ₹8 per share, scheduled a July 23, 2026 AGM, refreshed the Board with one re‑appointment and one new independent director, appointed Deloitte Haskins & Sells LLP as statutory auditors for five years, and elevated the India Generics head, Sandeep Khandelwal, to senior management.
Dr. Reddy’s Laboratories Limited filed a Form 6-K as a foreign private issuer to share access to its recent earnings call. The company provided an audio recording link for the earnings call held on May 12, 2026, covering the quarter ended March 31, 2026.
The intimation, signed by the Company Secretary and Compliance Officer, is addressed to multiple exchanges in India and the United States, indicating that the recording is available for information and record-keeping purposes for all listed venues.
Dr. Reddy’s Laboratories’ Board met on May 12, 2026 and approved several governance and leadership changes. It re-appointed Dr. K P Krishnan as an Independent Director for a second five-year term from January 7, 2027 to January 6, 2032, subject to shareholder approval.
The Board also approved Mr. Srikanth Velamakanni as an Additional Director, categorized as an Independent Director, for five years from July 1, 2026 to June 30, 2031, and appointed Deloitte Haskins & Sells LLP as Statutory Auditors for five years starting after the 42nd AGM. M/s Sagar & Associates were re-appointed as Cost Auditors for FY 2026-27.
Mr. Sandeep Khandelwal, Global Generics India Head, was elevated to Senior Management Personnel and inducted into the Management Council effective May 12, 2026. Under his leadership, the India business has grown its topline from Rs 2,300 crore to Rs 7,000 crore and expanded EBITDA margins from 19 percent to 24 percent, while scaling to a USD 750 million operation across six countries.
Dr. Reddy’s Laboratories Limited disclosed its upcoming analyst and institutional investor interactions. Management plans to attend an HSBC investor conference in Mumbai from May 14–15, 2026, and a Bank of America conference in Singapore from May 18–19, 2026. Both engagements are in-person group meetings during full business-day time slots, and the company notes that these schedules may change based on exigencies for either the investors or the company.
Dr. Reddy’s Laboratories Limited has approved new employee stock option grants. The committee granted 8,16,119 Indian stock options under the 2018 ESOP and 3,76,115 ADR stock options under the 2007 ADR scheme, each with an exercise price of Rs. 1,293.90 per share.
Both grants are in line with SEBI Share Based Employee Benefits and Sweat Equity Regulations, 2021, and will vest 100% at the end of 3 years, providing long‑term equity incentives for eligible employees across Indian and ADR programs.
Dr. Reddy’s Laboratories reports that it has received a Notice of Compliance from Health Canada for its generic Semaglutide Injection, authorizing commercialization, sale and distribution in Canada. The approval covers 2 mg/pen and 4 mg/pen strengths at 1.34 mg/mL and does not have a fixed expiry date. Dr. Reddy’s states it is the first company to obtain market authorization for generic Semaglutide Injection in Canada and has launch preparations underway. The company highlights that GLP‑1 receptor agonist therapies such as Semaglutide are supported by extensive clinical evidence for improving glycemic control in adults with type 2 diabetes and notes that Canada is recognized as the world’s second‑largest market for Semaglutide.